Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05793151 | Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy(ENDURE) | recruiting | N/A | 532 | Medical University of South CarolinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 |
| NCT06353906 | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer(PRIAM) | recruiting | Phase 2 | 27 | The Netherlands Cancer InstituteOTHER | 2 | Dec 8, 2025 | clinicaltrials |
| NCT07266493 | Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 26 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06576973 | Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06912087 | Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC | recruiting | Phase 1 | 36 | University of ChicagoOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05381597 | 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer | recruiting | Phase 2 / Phase 3 | 200 | Boston UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | recruiting | Phase 2 | 200 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05333523 | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.(PRIMO) | recruiting | Phase 3 | 242 | Radboud University Medical CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07081984 | Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors | recruiting | Phase 1 | 12 | TherornaINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07095608 | Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain | recruiting | N/A | 80 | New York UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06970145 | Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma | recruiting | Phase 1 / Phase 2 | 57 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06912074 | Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 134 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07086469 | Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)(SAVAL) | recruiting | Phase 2 | 61 | University of Maryland, BaltimoreOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05563766 | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | recruiting | Phase 2 | 78 | VA Office of Research and DevelopmentFED | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06914999 | Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer | recruiting | Early Phase 1 | 20 | Emory UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT06597565 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | recruiting | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06699212 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases(ECLIPSE) | recruiting | Phase 3 | 412 | Rakuten Medical, Inc.INDUSTRY | 3 | Oct 15, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT05945875 | Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer | recruiting | Phase 1 | 40 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06664151 | A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision | recruiting | Early Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06006169 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 186 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07111455 | Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy | recruiting | — | 32 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07188103 | Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03396718 | De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas(DELPHI) | recruiting | N/A | 304 | Technische Universität DresdenOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05582122 | SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers(SURVEILLE-HPV) | recruiting | Phase 2 | 420 | UNICANCEROTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06469008 | A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06536257 | Personalised Immunotherapy Platform(PIP-PREDICT) | recruiting | — | 1,000 | Melanoma Institute AustraliaOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07180901 | Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer(PRONTO-HN) | recruiting | N/A | 85 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07010692 | Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment | recruiting | Phase 1 / Phase 2 | 100 | Bruce Robinson, MDOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07177482 | ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients | recruiting | N/A | 20 | Deling LiOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06601309 | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC(ESCC) | recruiting | Phase 2 | 90 | Fujian Medical University Union HospitalOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07064330 | Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.(NGF-GRACE) | recruiting | — | 30 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06686342 | PDO Based Drug Sensitive Test in R/M HNSCC | recruiting | — | 100 | Huashan HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07152678 | Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma(BRIGHT-ESCC) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06509568 | Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） | recruiting | Phase 2 | 92 | Zhejiang Cancer HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07133958 | A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC | recruiting | — | 35 | Zhujiang HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT05446467 | Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC | recruiting | Phase 2 | 80 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07131566 | Immune Response in Cervical Lymph Nodes of Patients With Head and Neck Cancer | recruiting | — | 500 | Lars Olaf CardellOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY | 3 | Aug 15, 2025 | clinicaltrials |
| NCT06075264 | Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)(ART-VIN IIB) | recruiting | Phase 2 | 27 | Frantz Viral Therapeutics, LLCINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06492460 | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 422 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 11, 2025source: clinicaltrials